Vaccines and Preventable Diseases:

PCV7 (Pneumococcal Conjugate) Vaccine Articles
(Prevnar®)

Related articles

• Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination. Vaccine 2006;24(7):904-13. (Barzilay EJ, O'Brien KL, Kwok YS, et al.)
• Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 2006;144(1):1-9. (Flannery B, Heffernan RT, Harrison LH, et al.)
• Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006;25(9)779-81. (Hansen J, Black S, Shinefield H, et al.)
• Adults with invasive pneumococcal disease: missed opportunities for vaccination. American Journal of Preventive Medicine 2006;31(4):286-292. (Kyaw MH, Greene CM, Schaffner W, et al.)
• Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006;354(14):1455-63. (Kyaw MH, Lynfield R, Schaffner W, et al.)
• Pneumococcal vaccination in developing countries. Lancet 2006;367(9526):1880-2. (Levine OS, O'Brien KL, Knoll M, et al.)
• Usefulness of C-reactive protein to define pneumococcal conjugate vaccine efficacy in the prevention of pneumonia. Pediatr Infect Dis J 2006;25(1):30-6. (Madhi SA, Kohler M, Kuwanda L, Cutland C, Klugman KP.)
• Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine 2006;24(14):2514-20. (Mahon BE, Hsu K, Karumuri S, Kaplan SL, Mason EO, Jr., Pelton SI.)
• Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine 2006;24(4):468-75. (Metlay JP, Fishman NO, Joffe M, Edelstein PH.)
• Sequential Multiplex PCR Approach for Determining Capsular Serotypes of Streptococcus pneumoniae Isolates. J Clin Microbiol 2006;44(1):124-31. (Pai R, Gertz RE, Beall B.)
• Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006;295(14):1668-74. (Poehling KA, Talbot TR, Griffin MR, et al.)
• Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006;367(9512):740-8. (Prymula R, Peeters P, Chrobok V, et al.)
• Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006;25(6):494-501. (Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB.)
• Invasive pneumococcal disease in Australia, 2004. Commun Dis Intell 2006;30(1):80-92. (Roche PW, Krause VL, Bartlett M, et al.)
• The preventable burden of pneumococcal disease in the developing world. Vaccine 2006. (Scott JA.)
• Capsular Serotype-Specific Attack Rates and Duration of Carriage of Streptococcus pneumoniae in a Population of Children. J Infect Dis 2006;194(5):682-8. (Sleeman KL, Griffiths D, Shackley F, et al. )
• Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006;368(9546):1495-502. (Whitney CG, Pilishvili T, Farley MM, et al.)
• Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis 2007;195(3):347-52. (Hanage WP, Huang SS, Lipsitch M, et al.)
• Infectious Diseases Society of America / American Thoracic Society Consensus Guidelines on the Management of Community-acquired Pneumonia in Adults. Clin Infect Dis 2007;44 Suppl 2:S27-72. (Mandell LA, Wunderink RG, Anzueto A, et al.)
• Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007;369(9559):389-96. (Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA.)
• Impact of Conjugate Pneumococcal Vaccines (exit)
  The Pediatric Infectious Disease Journal: Volume 24(8) August 2005 pp 729-730
• Population-Based Impact of PCV in Young Children (exit)
  PEDIATRICS Vol. 114 No. 3 September 2004, pp. 755-761
• Potential Impact of Conjugate Pneumococcal Vaccines on Pediatric Pneumococcal Diseases
  American Journal of Epidemiology. 159(7):634-644, April 1, 2004 (exit)
• Impact of the PCV on Otitis Media (exit)
  The Pediatric Infectious Disease Journal: Volume 22(1) January 2003 pp 10-16
• Effectiveness of Heptavalent Pneumococcal Conjugate Vaccine in Children <5 Years Old for Prevention of Pneumonia (exit)
  The Pediatric Infectious Disease Journal: Volume 21(9) September 2002 pp 810-815
• The Future of Pneumococcal Conjugate Vaccines for Prevention of Pneumococcal Diseases in Infants and Children (exit)
  PEDIATRICS Vol. 110 No. 4 October 2002, pp. 805-814

 Return to main Pneumococcal Vaccination page

• Email this page
• Printer-friendly version

• Help
• Glossary / Acronyms
• Site Map